Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Itamar Raz

Showing results (191-200 of 254) with videos related to

Pageof 26
Sort By:
Nature Medicine|June 8, 2026
Effects of SGLT2 inhibition on incident heart failure in carriers of cardiomyopathy-associated genetic variantsNicholas A Marston, Shinwan Kany, Giorgio E M Melloni, et al.
Diabetes Care|December 22, 2017
Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a <i>Diabetes Care</i> Editors' Expert ForumWilliam T Cefalu, Sanjay Kaul, Hertzel C Gerstein, et al.
Annals of the New York Academy of Sciences|October 4, 2007
CD44 involvement in autoimmune inflammations: the lesson to be learned from CD44-targeting by antibody or from knockout miceDavid Naor, Shlomo Nedvetzki, Marita Walmsley, et al.
Cardiovascular Diabetology|October 7, 2020
Adolescent BMI and early-onset type 2 diabetes among Ethiopian immigrants and their descendants: a nationwide studyMaya Simchoni, Uri Hamiel, Orit Pinhas-Hamiel, et al.
Diabetes Care|May 25, 2013
Personalized management of hyperglycemia in type 2 diabetes: reflections from a Diabetes Care Editors' Expert ForumItamar Raz, Matthew C Riddle, Julio Rosenstock, et al.
The Journal of Clinical Endocrinology and Metabolism|May 29, 2021
Adolescent Thyroid Disorders and Risk for Type 2 Diabetes in Young AdulthoodAya Bardugo, Estela Derazne, Inbar Zucker, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|August 30, 2011
Sulodexide for kidney protection in type 2 diabetes patients with microalbuminuria: a randomized controlled trialEdmund J Lewis, Julia B Lewis, Tom Greene, et al.
Journal of the American Society of Nephrology : JASN|October 29, 2011
Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathyDavid K Packham, Rory Wolfe, Anne T Reutens, et al.
Pharmaceuticals (Basel, Switzerland)|August 28, 2025
SGLT2 Inhibitors in MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease) Associated with Sustained Hepatic Benefits, Besides the CardiometabolicMohamad Suki, Ashraf Imam, Johnny Amer, et al.
ESC Heart Failure|September 15, 2025
Galectin-3 and kidney function in type 2 diabetes treated with dapagliflozin: Analysis from DECLARE-TIMI 58Paul M Haller, Stephen D Wiviott, David D Berg, et al.
Pageof 26

Showing results (191-200 of 254) with videos related to

Sort By:
Pageof 26
Nature Medicine|June 8, 2026
Effects of SGLT2 inhibition on incident heart failure in carriers of cardiomyopathy-associated genetic variantsNicholas A Marston, Shinwan Kany, Giorgio E M Melloni, et al.
Diabetes Care|December 22, 2017
Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a <i>Diabetes Care</i> Editors' Expert ForumWilliam T Cefalu, Sanjay Kaul, Hertzel C Gerstein, et al.
Annals of the New York Academy of Sciences|October 4, 2007
CD44 involvement in autoimmune inflammations: the lesson to be learned from CD44-targeting by antibody or from knockout miceDavid Naor, Shlomo Nedvetzki, Marita Walmsley, et al.
Cardiovascular Diabetology|October 7, 2020
Adolescent BMI and early-onset type 2 diabetes among Ethiopian immigrants and their descendants: a nationwide studyMaya Simchoni, Uri Hamiel, Orit Pinhas-Hamiel, et al.
Diabetes Care|May 25, 2013
Personalized management of hyperglycemia in type 2 diabetes: reflections from a Diabetes Care Editors' Expert ForumItamar Raz, Matthew C Riddle, Julio Rosenstock, et al.
The Journal of Clinical Endocrinology and Metabolism|May 29, 2021
Adolescent Thyroid Disorders and Risk for Type 2 Diabetes in Young AdulthoodAya Bardugo, Estela Derazne, Inbar Zucker, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|August 30, 2011
Sulodexide for kidney protection in type 2 diabetes patients with microalbuminuria: a randomized controlled trialEdmund J Lewis, Julia B Lewis, Tom Greene, et al.
Journal of the American Society of Nephrology : JASN|October 29, 2011
Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathyDavid K Packham, Rory Wolfe, Anne T Reutens, et al.
Pharmaceuticals (Basel, Switzerland)|August 28, 2025
SGLT2 Inhibitors in MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease) Associated with Sustained Hepatic Benefits, Besides the CardiometabolicMohamad Suki, Ashraf Imam, Johnny Amer, et al.
ESC Heart Failure|September 15, 2025
Galectin-3 and kidney function in type 2 diabetes treated with dapagliflozin: Analysis from DECLARE-TIMI 58Paul M Haller, Stephen D Wiviott, David D Berg, et al.
Pageof 26